[Juvenile parkinsonism in monozygotic twins].
Rinsho Shinkeigaku
Department of Neurology, Kagoshima Prefectural Ohshima Hospital.
Published: March 1991
A pair of monozygotic twins concordant for juvenile Parkinsonism are described. These twin sisters have lived together until 18 years old. Twin A noted tremor in the right hand and right-sided stiffness and slowness at the age 20. Initially, a marked improvement was shown with L-dopa treatment. However, one year after the beginning of treatment, dopa-induced dyskinesia appeared. Twin B noted tremor and right-sided stiffness and basal ganglia calcification in both patients. These twin patients suggest that genetic factors may play an important role in the cause of juvenile Parkinsonism.
Download full-text PDF |
Source |
|---|
Similar Publications
A decision aid is not the quick fix for improving shared decision-making in advanced Parkinson's disease: results of a mixed methods feasibility study.
J Neurol
March 2025
Department of Neurology, Center of Expertise for Parkinson and Movement Disorders, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Background: Choosing a device-assisted treatment for persons with Parkinson's disease (PwPD) is a complex decision. We developed a shared decision-making (SDM) intervention to facilitate this decision. In this study, we evaluate the feasibility of this intervention from the patients' perspective.
View Article and Find Full Text PDFJoint examination of reflexive vertical saccades and small involuntary fixational saccades improves the classification of patients with progressive supranuclear palsy (PSP): a ROC study.
Exp Brain Res
March 2025
Section of Neurophysiology, Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.
A slowing of saccadic eye movements is one of the key symptoms of progressive supranuclear palsy and therefore represents a core functional domain of the current diagnostic criteria. However, there is considerable overlap between the saccade velocities of healthy people and patients in early stages. Therefore, a highly specific discrimination between patients and controls based on eye velocity often results in a considerable loss of sensitivity.
View Article and Find Full Text PDFEarly Detection and Management of Cognitive Impairment in Parkinson's Disease: A Predictive Model Approach.
Brain Behav
March 2025
Shanxi Key Laboratory of Otorhinolaryngology-Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
Objective: The study aims to identify risk factors associated with cognitive impairment in Parkinson's disease and to develop a predictive model to facilitate early clinical detection, diagnosis, and management, thereby enhancing patient prognosis and quality of life.
Methods: A total of 351 PD patients were enrolled from the Department of Neurology at the First Hospital of Shanxi Medical University between January 2022 and December 2023. Cognitive function was evaluated using the Montreal Cognitive Assessment (MoCA) scale, and patients were subsequently categorized into cognitively normal (PD-NC) and cognitively impaired (PD-CI) groups.
[Overview of therapeutic strategies for motor disturbances in Parkinson's disease].
Rev Med Liege
March 2025
Faculté de Médecine, département des sciences biomédicales et précliniques, Groupe MoVeRe, GIGA Neurosciences, ULiège, Belgique.
Parkinson's disease is an adult neurodegenerative disorder whose prevalence continues to rise. There is no proven therapeutic strategy capable of interfering with its unfavourable evolutionary profile. Current treatments remain symptomatic.
View Article and Find Full Text PDFLRRK2 in Drosophila Melanogaster Model: Insights into Cellular Dysfunction and Neuroinflammation in Parkinson's Disease.
Int J Mol Sci
February 2025
Department of Biomedical Sciences, University of Sassari, via Francesco Muroni 25, 07100 Sassari, Italy.
Parkinson's disease (PD) is a fatal neurodegenerative disease for which there are no still effective treatments able to stop or slow down neurodegeneration. To date, pathological mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified as the major genetic cause of PD, although the molecular mechanism responsible for the loss of dopaminergic neurons is still cryptic. In this review, we explore the contribution of Drosophila models to the elucidation of LRRK2 function in different cellular pathways in either neurons or glial cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.